In addition, members of the management team will present at the following upcoming investor conferences:
Jefferies 2019 Healthcare Conference,
Tuesday, June 4, at 11:30 am ETat The Grand Hyatt, New York, NY Goldman Sachs40th Annual Healthcare Conference, Tuesday, June 11at 10:00 am PTat the Terranea Resort, Rancho Palos Verdes, CA
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that the preliminary positive efficacy and safety results
from our prior and ongoing clinical trials of our product candidates
will not continue or be repeated in our ongoing or planned clinical
trials; risks that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory submissions
or to support marketing approval in the U.S. and EU; and the risk that
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent Form 10-Q as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the
Source: bluebird bio, Inc.